JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB305279

Human TICAM1 knockout U-87MG cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TICAM1 KO cell line available to order. KO validated by. Free of charge wild type control available. Homozygote. 392 bp deletion. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
2 Images
Western blot - Human TICAM1 knockout U-87MG cell line (AB305279)
  • WB

Collaborator

Western blot - Human TICAM1 knockout U-87MG cell line (AB305279)

ab302562 was shown to react with TICAM1 in wild-type U-87 MG cells in Western blot with loss of signal observed in TICAM1 knockout cell line ab305279. Wild-type U-87 MG and TICAM1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 5% milk in TBST for 1 hr before incubation with ab302562 overnight at 4 °C at a 1/1000 dilution. Blots were incubated with secondary antibodies at 0.2 µg/mL before imaging.

This data was provided by YCharOS Inc., an open science company with the mission of characterizing commercially available antibody reagents for all human proteins. Abcam and YCharOS are working together to help address the reproducibility crisis by enabling the life science community to better evaluate commercially available antibodies.

All lanes:

Western blot at 1/1000 dilution

Lane 1:

Wild-type U-87 MG lysate at 30 µg

Lane 2:

Western blot - Human TICAM1 knockout U-87MG cell line (ab305279) at 30 µg

Lane 2:

TICAM1 knock-out U-87 MG lysate at 30 µg

false

Sanger Sequencing - Human TICAM1 knockout U-87MG cell line (AB305279)
  • Sanger seq

Supplier Data

Sanger Sequencing - Human TICAM1 knockout U-87MG cell line (AB305279)

Homozygote. 392 bp deletion

Key facts

Cell type

U-87 MG

Species or organism

Human

Tissue

Brain

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Homozygote. 392 bp deletion

Disease

Glioblastoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Sanger seq": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Recommended control: Human wild-type U-87 MG cell line (ab278079). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

Cryopreservation cell medium: Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Culture medium: EMEM + 10% FBS

Initial handling guidelines: Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules.
4. Incubate the culture at 37°C incubator with 5% CO2. Cultures should be monitored daily.

Subculture guidelines:

  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • A partial media change 24 hours prior to subculture may be helpful to encourage growth, if required.
  • Cells should be passaged when they have achieved 80-90% confluence.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Properties and storage information

Gene name
TICAM1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage duration
A few days
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

EMEM + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRIF also known as TIR-domain-containing adapter-inducing interferon-β is an adapter protein that plays an important role in the immune response. It has a molecular mass of about 85 kDa. TRIF is expressed in various tissues but most highly in immune cells like macrophages and dendritic cells. Mechanically TRIF acts within the signaling pathways by connecting Toll-like receptors (TLR) with downstream signaling molecules. It is essential for activating pathways that lead to the production of type I interferons and other cytokines.
Biological function summary

TRIF is part of the innate immune response mechanism. It functions as a central component in signal transduction processes especially in response to pathogen-associated molecular patterns (PAMPs). TRIF often forms complexes with other signaling proteins to activate transcription factors such as IRF3 and NF-kB which stimulate the expression of inflammatory cytokines and antiviral genes. This function allows the body to respond quickly to infections and initiate immune defenses.

Pathways

TRIF participates in important immune signaling pathways notably the TLR and interferon signaling pathways. In the TLR pathway TRIF interacts with proteins such as MyD88 and TRAF6 to propagate signals from TLR4 critical in detecting Gram-negative bacteria. Through its role in the interferon signaling pathway TRIF helps in the regulation of antiviral responses and is essential for the expression of interferon-stimulated genes that combat viral infections.

TRIF is associated with conditions involving abnormal immune responses such as autoimmune disorders and sepsis. Dysregulation of TRIF-mediated signaling can lead to excessive inflammation or defective immune responses contributing to disease pathogenesis. For example an overactive TRIF pathway may lead to increased susceptibility to sepsis due to augmented inflammatory cytokine production. TRIF also connects with proteins like IRF3 and NF-kB which are often implicated in autoimmune conditions due to their roles in persistent inflammation and immune cell activation.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com